Table 1 Demographic data and clinical characteristics of patients with non-cirrhotic NAFLD and cirrhotic NAFLD
| Â | Non-cirrhotic NAFLD n (%) | Cirrhotic NAFLD n (%) | P value |
|---|---|---|---|
Total | 367,690 (100) | 25,110 (100) | Â |
Gender |  |  | < 0.001 |
 Male gender | 153,250 (41.7) | 9380 (37.4) |  |
 Female gender | 214,440 (58.3) | 15,730 (62.6) |  |
Age group |  |  | < 0.001 |
 Age > 65 years | 126,100 (34.3) | 13,860 (55.2) |  |
 Age 18–65 years | 241,590 (65.7) | 11,250 (44.8) |  |
Race |  |  | < 0.001 |
 Non-Hispanic white | 303,750 (82.6) | 21,910 (87.3) |  |
 Non-Hispanic black | 31,510 (8.6) | 1240 (4.9) |  |
 Hispanic | 6260 (1.7) | 560 (2.2) |  |
 Others/unknown | 26,170 (7.1) | 1400 (5.6) |  |
Comorbidities | Â | Â | Â |
 Obesity | 187,820 (51.1) | 13,810 (55.0) | < 0.001 |
 Morbid obesity | 91,790 (25.0) | 7560 (30.1) | < 0.001 |
 Diabetes mellitus | 154,710 (42.1) | 16,860 (67.1) | < 0.001 |
 Hypertension | 255,190 (69.4) | 20,120 (80.1) | < 0.001 |
 Hyperlipidemia | 256,880 (69.9) | 17,480 (69.6) | 0.405 |
Smoker | 54,870 (14.9) | 5310 (21.1) | < 0.001 |
Laboratory data | Â | Â | Â |
 High ALT | 166,910 (45.4) | 13,250 (52.8) | < 0.001 |
Medication use | Â | Â | Â |
 Statin | 177,160 (48.2) | 13,060 (52.0) | < 0.001 |
 ACEI or ARBs | 197,440 (53.7) | 15,950 (63.5) | < 0.001 |
 Metformin | 113,480 (30.9) | 10,550 (42.0) | < 0.001 |
 Sulfonylurea | 50,940 (13.9) | 6420 (25.6) | < 0.001 |
 Thiazolidinedione | 16,170 (4.4) | 1890 (7.5) | < 0.001 |
 Insulin | 82,900 (22.6) | 12,530 (49.9) | < 0.001 |
Liver decompensation | – | 14,690 (58.5) |  |
 Variceal bleeding | – | 1590 (6.3) |  |
 Hepatic encephalopathy | – | 3830 (15.3) |  |
 Ascites | – | 7420 (29.6) |  |
 Elevated bilirubin | – | 10,130 (40.3) |  |
HCC | 170 (0.000462) | 940 (0.037435) | < 0.001 |